Bayer Diabetes Care – a new sponsor of Glycosmedia
A warm welcome to Bayer Diabetes Care who join Abbott Diabetes Care and Novo Nordisk as sponsors of Glycosmedia. Companies and organisations who are interested in sponsoring Glycosmedia can contact the Editor-in-chief Jim Young for further details. jim@glycosmedia.com
Diabetes Action Plan 2010: Quality Care for Diabetes in Scotland
This Action Plan is a continuation of the range of work set out in the Scottish Diabetes Action Plan published in 2006 (Scottish Government, UK)
A Review and Update of Insulins in the Management of Elderly Patients with Diabetes
Elderly people are at higher risk for hypoglycemia … Target HbA1c should be always be individualized in elderly patients based on their functional status, life expectancy, and cognitive function (Clinical Geriatrics)
Dipeptidyl peptidase-4 inhibitors (‘gliptins’) for type 2 diabetes mellitus
Information for healthcare professionals (National Prescribing Service, Australia)
Nine-year incident diabetes is predicted by fatty liver indices
These fatty liver indexes are simple clinical tools for evaluating the extent of liver fat and they are predictive of incident diabetes (BMC Gastroenterology)
Barriers to achieving targets, risks of hyperglycemia and hypoglycemia in children
There is an increasing body of evidence that hyperglycemia may beget further hyperglycemia through neurobehavioral pathways, and that hyperglycemia can be associated with anatomic as well as cognitive alterations in central nervous system morphology and function (Endocrine Today)
Changes in GAD65Ab-Specific Antiidiotypic Antibody Levels
Changes in GAD65Ab-Specific Antiidiotypic Antibody Levels Correlate with Changes in C-Peptide Levels and Progression to Islet Cell Autoimmunity . The close association between GAD65Ab-specific anti-Id levels and beta-cell function may provide a novel marker for the progression of autoimmune diabetes (Journal of Clinical Endocrinology & Metabolism)
Diabetes: Hospital Bills Cost Americans $83B A Year
A new report finds diabetes accounts for nearly $1 out of $4 spent on hospital care (The Fiscal TIMES)
Revisiting the Rosiglitazone Story — Lessons Learned
Three lines of evidence have emerged since 2007 suggesting that rosiglitazone’s cardiovascular risk is significant and that major federal action is now required (New England Journal of Medicine)
Novo Nordisk Creates “App” to Help Doctors Dose Insulin, Supporting New Trend in Diabetes Care
Novo Nordisk announced today the availability of NovoDose™ – the first-ever mobile insulin dosing guide for physicians to look up dosing guidelines and blood glucose goals for their patients with diabetes (PR Newswire)
Glycosmedia is also available as an App: